CD19-directed CAR T-cell therapy (CART19) has transformed relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) management, but the prognostic impact of immunotherapy sensitivity and post-allogeneic hematopoietic cell transplantation (alloHCT) relapse timing in real-world practice remains unclear. We re...
V. Ortíz-Maldonado, J. Galimard, Giorgio Ottaviano et al.· Blood Advances· 0 citations
In AML patients receiving alloHSCT with PTCy, outcomes were largely similar regardless of whether CR1 was achieved after one or two-induction courses, with relapse incidence being higher in patients requiring 2 inductions.
A. Nagler, R. Swoboda, Allain-Thibeault Ferhat et al.· Bone Marrow Transplantation· 0 citations
The EBMT community strongly supports an expanded global role focused on education, capacity building, and collaboration in underserved regions, and support for LMIC capacity building.
A. Nagler, N. Gorin, C. Chabannon et al.· Bone Marrow Transplantation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.